The use of bicyclol in the treatment of severe liver fibrosis: experimental rationale

Aim. To evaluate the antifibrotic effect of bicyclol with promising clinical effects on diffuse parenchymal liver diseases.

Materials and methods: We have included 40 adult male Wistar rats (weight, 180 to 200g) with experimentally inducted toxic F3 stage liver fibrosis. Control group consisted of 16 rats that received standart chow, experimental group of 24 rats also received 30-day bicyclol supply. To evaluate the results we used histological, biochemical, molecular genetic and statistical methods.

Results. In experimental group interlobular fibrosis was maintained in 4,16% (p<0,001) of cases after the end of the therapy, stromal fibrosis of portal tracts was observed in 62,5% (p<0,001) of cases. Periportal fibrosis detection rate in experimental group was 66,7% (p<0,001). Rats from experimental group showed regression of liver fibrosis to F1- F2 stage in 16,6% (METAVIR) whereas control group had F3 stage liver fibrosis in 62,5% (p <0,05). Statistically significant increase in ALT activity and decreased total protein levels in control group were observed. No changes in gut microbiome profile in experimental animals were found.

Conclusion. Use of bicyclol led to pronounced suppression of liver fibrotic changes in laboratory animals and temporary decreased serum ALT level. Our study showed no link between therapeutic effects of the drug and gut microbiome status.

1. Global’naja strategija sektora zdravoohranenija po virusnomu gepatitu 2016-2021 [Internet]. World Health Organization; 2016 [cited 2020 Jul 27]. Available from: https://apps.who.int/iris/bitstream/handle/10665/250042/WHO-HIV-2016.06-rus.pdf;jsessionid=3305A8ADD24EF0B4216E4BDA82AA4667?sequence=1/.

2. Preparat Biciklol v lechenii gepatitov razlichnoj jetiologii. Vtoraja rossijsko-kitajskaja konferencija, posvjashhennaja original’nomu lekarstvennomu preparatu Biciklol [Internet]. Universal Medical Portal; 2015 [cited 2020 Jul 27]. Available from: https://umedp.ru/articles/preparat_bitsiklol_v_lechenii_gepatitov_razlichnoy_etiologii_vtoraya_rossiyskokitayskaya_konferentsi.html/.

3. Federal’nyj zakon «O veterinarii» tekst s izmenenijami i dopolnenijami na 2020 g. [Internet]. Garant; spravochno-pravovaja sistema; 2020 [cited 2020 Jul 27]. Available from: https://base.garant.ru/10108225/.

4. Rekomendacii Komitetam po Jetike, provodjashhim jekspertizu biomedicinskih issledovanij / World Health Organization. – Moscow; Geneva, 2000. – 36 p.

5. Direktiva Evropejskogo parlamenta i Soveta Evropejskogo Sojuza 2010/63/ES ot 22 sent. 2010g. o zashhite zhivotnyh, ispol’zujushhihsja dlja nauchnyh celej [Internet]. Garant; spravochno-pravovaja sistema; 2020 [cited 2020 Jul 27]. Available from: https://base.garant.ru/70350564/.

6. Zhdanov, K.V. Sravnitel’naja ocenka jeffektivnosti primenenija aspiracionnoj i avtomaticheskoj sistem dlja perkutannoj biopsii pecheni u jeksperimental’nyh krys / K.V. Zhdanov, K.V. Kozlov, A.V. Saulevich, V.S. Sukachev i dr. // Vestnik Rossijskoj Voenno-medicinskoj akademii. – 2019. – Т. 66, № 2. – P. 96-101.

7. Saulevich, A.V. Kliniko-jeksperimental’noe obosnovanie korrekcii disbioza kishechnika u bol’nyh virusnymi cirrozami pecheni [dissertation]. [Saint Petersburg]: VMedA; 2019. – 109 p.

8. Skuratov, A.G. Tetrahlormetanovaja model’ gepatita i cirroza pecheni u krys / A.G. Skuratov // Jeksperimental’naja i klinicheskaja gastrojenterologija. – 2012. – №9. – P. 37–40.

9. Isakov, V.A. Sovremennye metody ocenki vyrazhennosti fibroza pecheni / V.A. Isakov, S.V. Morozov, B.S. Kaganov // Infekcionnye bolezni. – 2009. – №4. – P. 44–49.

10. Karev, V.E. Klinicheskie i immuno-morfologicheskie aspekty patogeneza hronicheskoj HBV– i HCV–infekcii [master’s thesis]. [Saint Petersburg]: VMedA; 2016. – 22 p.

11. Cinzerling, A.V. Sovremennye infekcii: patologicheskaja anatomija i voprosy patogeneza: rukovodstvo / A.V. Cinzerling, V.A. Cinzerling. – 2-e izd., dop. i ispr. – Sankt-Peterburg : Sotis, 2002. – 346 p. – ISBN 5-85503-805-7.

12. Cinzerling, V.A. Kliniko-morfologicheskie sopostavlenija pri okkul’tnom gepatite B / V.A. Cinzerling i dr. // Arhiv patologii. – 2017. – Т. 79, № 6. – P. 8–13.

13. Bedossa, P. An algorithm for the grading of activity in chronic hepatitis C / P. Bedossa, T. Poynard // Hepatology. – 1996. – Vol. 24. – P. 289–293.

14. Desmet, V.J. Classification of chronic hepatitis: diagnosis, grading and staging / V.J. Desmet, M. Gerber, J.H. Hoofnagle, M. Manns et al. // Hepatology. – 1994. – Vol. 19, №. 6. – P. 1513–1520.

15. Jocelyn, H. Histopathologic techniques / H. Jocelyn, M.D. Bruce-Gregorios. – Philippines: Good Will Bookstore, 1974. – 600 p. – ISBN 978-1521524701.

16. Knodell, R.G. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis / R.G. Knodell, K.G. Ishak, W.C. Black, T.S. Chen et al. // Hepatology. – 1981. – Vol. 1, №. 5. – P. 431–435.

17. Metody laboratornoj diagnostiki virusnyh boleznej zhivotnyh: spravochnik / Sjurin V.N., Belousova R.V., Solov’ev B.V. i dr.- Moskva : Agropromizdat, 1986. – 351 p.

18. Tarasova, E.A. Jekspress–diagnostika ostryh kishechnyh infekcij metodom PCR / E.A Tarasova, M.A. Suvorova // Gastrojenterologija. – 2011. – №. 4. – P. М33–М33a.

19. Karjakin, S.S. Ocenka funkcional’nogo sostojanija kishechnika u bol’nyh hronicheskim gepatitom S s izbytochnoj massoj tela [dissertation]. [Saint Petersburg]: VMedA; 2019. – 131 p.